Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Improved survival rates of AML patients following admission to the intensive care unit.

Fassbind P, Jeker B, Mueller BU, Bacher U, Zimmerli S, Endrich O, Gahl B, Novak U, Pabst T.

Leuk Lymphoma. 2019 Apr 3:1-9. doi: 10.1080/10428194.2019.1594213. [Epub ahead of print]

PMID:
30943056
2.

Principles of Pediatric Patient Safety: Reducing Harm Due to Medical Care.

Mueller BU, Neuspiel DR, Fisher ERS; COUNCIL ON QUALITY IMPROVEMENT AND PATIENT SAFETY, COMMITTEE ON HOSPITAL CARE.

Pediatrics. 2019 Feb;143(2). pii: e20183649. doi: 10.1542/peds.2018-3649. Epub 2019 Jan 22.

PMID:
30670581
3.

Myelodysplastic syndromes and acute myeloid leukemias in the elderly.

Mueller BU, Seipel K, Pabst T.

Eur J Intern Med. 2018 Dec;58:28-32. doi: 10.1016/j.ejim.2018.05.026. Review.

PMID:
30527920
4.

Autologous Transplantation for Older Adults with AML.

Mueller BU, Seipel K, Bacher U, Pabst T.

Cancers (Basel). 2018 Sep 19;10(9). pii: E340. doi: 10.3390/cancers10090340. Review.

5.

Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.

Alva LC, Bacher U, Seipel K, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Transfusion. 2018 Oct;58(10):2365-2373. doi: 10.1111/trf.14895. Epub 2018 Sep 10.

PMID:
30203418
6.

Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.

Farag S, Jeker B, Bacher U, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Hematol Oncol. 2018 Oct;36(4):671-678. doi: 10.1002/hon.2546. Epub 2018 Sep 11.

PMID:
30110717
7.

MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin.

Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T.

Haematologica. 2018 Nov;103(11):1862-1872. doi: 10.3324/haematol.2018.191650. Epub 2018 Jul 5.

8.

Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma.

Moor I, Bacher VU, Jeker B, Taleghani BM, Mueller BU, Keller P, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2018 Dec;53(12):1599-1602. doi: 10.1038/s41409-018-0245-y. Epub 2018 Jun 8. No abstract available.

PMID:
29884856
9.

Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression.

Junge A, Bacher U, Mueller BU, Keller P, Solenthaler M, Pabst T.

Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2516. [Epub ahead of print]

PMID:
29862539
10.
11.

NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma.

Jeker B, Novak U, Mansouri Taleghani B, Baerlocher GM, Seipel K, Mueller BU, Bigler M, Betticher D, Luethi JM, Farese S, Ruefer A, Pabst T.

Bone Marrow Transplant. 2018 Feb;53(2):175-179. doi: 10.1038/bmt.2017.234. Epub 2017 Oct 23.

PMID:
29058701
12.

Creating a Pediatric Joint Council to Promote Patient Safety and Quality, Governance, and Accountability Across Johns Hopkins Medicine.

Rosen M, Mueller BU, Milstone AM, Remus DR, Demski R, Pronovost PJ, Miller MR.

Jt Comm J Qual Patient Saf. 2017 May;43(5):224-231. doi: 10.1016/j.jcjq.2017.02.006. Epub 2017 Mar 28.

PMID:
28434455
13.

Identifying existing Choosing Wisely recommendations of high relevance and importance to hematology.

Hicks LK, Rajasekhar A, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Sarode R, Wood WA.

Am J Hematol. 2016 Aug;91(8):787-92. doi: 10.1002/ajh.24412. Epub 2016 Jun 8.

14.

Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.

Seipel K, Marques MT, Bozzini MA, Meinken C, Mueller BU, Pabst T.

Clin Cancer Res. 2016 Feb 1;22(3):746-56. doi: 10.1158/1078-0432.CCR-15-1054. Epub 2015 Sep 25.

15.

Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.

Mueller BU, Keller S, Seipel K, Mansouri Taleghani B, Rauch D, Betticher D, Egger T, Pabst T.

Leuk Lymphoma. 2016 May;57(5):1122-9. doi: 10.3109/10428194.2015.1079315. Epub 2015 Oct 12.

16.

Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment.

Keller S, Seipel K, Novak U, Mueller BU, Taleghani BM, Leibundgut K, Pabst T.

Leuk Res. 2015 Jul;39(7):786-92. doi: 10.1016/j.leukres.2015.03.015. Epub 2015 Mar 28.

PMID:
25891070
17.

CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma.

Berger MD, Branger G, Leibundgut K, Baerlocher GM, Seipel K, Mueller BU, Gregor M, Ruefer A, Pabst T.

Leuk Res. 2015 Jun;39(6):561-7. doi: 10.1016/j.leukres.2015.03.004. Epub 2015 Mar 19.

PMID:
25890431
18.

Five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):599-603. doi: 10.1182/asheducation-2014.1.599. Epub 2014 Nov 18.

PMID:
25696917
19.

Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma.

Berger MD, Branger G, Klaeser B, Taleghani BM, Novak U, Banz Y, Mueller BU, Pabst T.

Hematol Oncol. 2016 Sep;34(3):133-9. doi: 10.1002/hon.2197. Epub 2015 Feb 17.

PMID:
25689832
20.

Consolidation of first remission using radioimmunotherapy with yttrium-90-ibritumomab-tiuxetan in adult patients with Burkitt lymphoma.

Koechli V, Klaeser B, Banz Y, Mueller BU, Pabst T.

Leuk Res. 2015 Mar;39(3):307-10. doi: 10.1016/j.leukres.2014.12.016. Epub 2015 Jan 7.

PMID:
25616614
21.

Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.

Kamber C, Zimmerli S, Suter-Riniker F, Mueller BU, Taleghani BM, Betticher D, Zander T, Pabst T.

Bone Marrow Transplant. 2015 Apr;50(4):573-8. doi: 10.1038/bmt.2014.290. Epub 2015 Jan 19.

PMID:
25599166
22.

Five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA.

Blood. 2014 Dec 4;124(24):3524-8. doi: 10.1182/blood-2014-09-599399.

23.

Delayed Haematological recovery after autologous stem cell transplantation is associated with favourable outcome in acute myeloid leukaemia.

Wetzel D, Mueller BU, Mansouri Taleghani B, Baerlocher GM, Seipel K, Leibundgut K, Pabst T.

Br J Haematol. 2015 Jan;168(2):268-73. doi: 10.1111/bjh.13118. Epub 2014 Sep 12.

PMID:
25212255
24.

Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial).

Schmid A, Friess D, Mansouri Taleghani B, Keller P, Mueller BU, Baerlocher GM, Leibundgut K, Pabst T.

Leuk Lymphoma. 2015 Mar;56(3):608-14. doi: 10.3109/10428194.2014.927454. Epub 2014 Aug 4.

PMID:
24884311
25.

Quality and safety in pediatric hematology/oncology.

Mueller BU.

Pediatr Blood Cancer. 2014 Jun;61(6):966-9. doi: 10.1002/pbc.24946. Epub 2014 Jan 31. Review.

PMID:
24481936
26.

The ASH Choosing Wisely®campaign: five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA.

Hematology Am Soc Hematol Educ Program. 2013;2013:9-14. doi: 10.1182/asheducation-2013.1.9.

PMID:
24319155
27.

The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question.

Hicks LK, Bering H, Carson KR, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Pasquini M, Sarode R, Solberg L Jr, Haynes AE, Crowther MA.

Blood. 2013 Dec 5;122(24):3879-83. doi: 10.1182/blood-2013-07-518423. Epub 2013 Dec 4.

28.

Association of care in a medical home and health care utilization among children with sickle cell disease.

Raphael JL, Rattler TL, Kowalkowski MA, Brousseau DC, Mueller BU, Giordano TP.

J Natl Med Assoc. 2013 Summer;105(2):157-65.

29.
30.

Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.

31.

Trends in blood transfusion among hospitalized children with sickle cell disease.

Raphael JL, Oyeku SO, Kowalkowski MA, Mueller BU, Ellison AM.

Pediatr Blood Cancer. 2013 Nov;60(11):1753-8. doi: 10.1002/pbc.24630. Epub 2013 Jun 18.

32.

Parental information, motivation, and adherence behaviors among children with sickle cell disease.

Raphael JL, Butler AM, Rattler TL, Kowalkowski MA, Mueller BU, Giordano TP.

Pediatr Blood Cancer. 2013 Jul;60(7):1204-10. doi: 10.1002/pbc.24466. Epub 2013 Jan 9.

33.

The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients.

Mans S, Banz Y, Mueller BU, Pabst T.

Blood. 2012 Sep 27;120(13):2690-9. Epub 2012 Aug 22.

34.

The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential.

von Grünigen I, Raschle J, Rüsges-Wolter I, Taleghani BM, Mueller BU, Pabst T.

Leuk Res. 2012 Nov;36(11):1325-9. doi: 10.1016/j.leukres.2012.05.027. Epub 2012 Jun 23.

PMID:
22727508
35.

The second century of sickle cell disease.

Ware RE, Mueller BU.

Pediatr Blood Cancer. 2012 Aug;59(2):352. doi: 10.1002/pbc.24181. Epub 2012 May 4. No abstract available.

PMID:
22566393
36.

The medical home experience among children with sickle cell disease.

Raphael JL, Rattler TL, Kowalkowski MA, Mueller BU, Giordano TP.

Pediatr Blood Cancer. 2013 Feb;60(2):275-80. doi: 10.1002/pbc.24184. Epub 2012 Apr 22.

37.

Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort.

Kwiatkowski JL, Kim HY, Thompson AA, Quinn CT, Mueller BU, Odame I, Giardina PJ, Vichinsky EP, Boudreaux JM, Cohen AR, Porter JB, Coates T, Olivieri NF, Neufeld EJ; Thalassemia Clinical Research Network.

Blood. 2012 Mar 22;119(12):2746-53. doi: 10.1182/blood-2011-04-344507. Epub 2012 Jan 25.

38.

Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.

Aygun B, Wruck LM, Schultz WH, Mueller BU, Brown C, Luchtman-Jones L, Jackson S, Iyer R, Rogers ZR, Sarnaik S, Thompson AA, Gauger C, Helms RW, Ware RE; TCD With Transfusions Changing to Hydroxyurea (TWiTCH) Trial Investigators.

Am J Hematol. 2012 Apr;87(4):428-30. doi: 10.1002/ajh.23105. Epub 2012 Jan 9. No abstract available.

39.

Shorter hospitalization trends among children with sickle cell disease.

Raphael JL, Mueller BU, Kowalkowski MA, Oyeku SO.

Pediatr Blood Cancer. 2012 Oct;59(4):679-84. doi: 10.1002/pbc.24065. Epub 2012 Jan 4.

PMID:
22223395
40.

High levels of circulating CD34+ cells at autologous stem cell collection are associated with favourable prognosis in multiple myeloma.

Raschle J, Ratschiller D, Mans S, Mueller BU, Pabst T.

Br J Cancer. 2011 Sep 27;105(7):970-4. doi: 10.1038/bjc.2011.329. Epub 2011 Aug 30.

41.

High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease.

Raphael JL, Mei M, Mueller BU, Giordano T.

Pediatr Blood Cancer. 2012 Apr;58(4):584-90. doi: 10.1002/pbc.23181. Epub 2011 May 16.

PMID:
21584938
42.

Translating scientific advances to improved outcomes for children with sickle cell disease: a timely opportunity.

Raphael JL, Kavanagh PL, Wang CJ, Mueller BU, Zuckerman B.

Pediatr Blood Cancer. 2011 Jul 1;56(7):1005-8. doi: 10.1002/pbc.23059. Epub 2011 Feb 22.

PMID:
21488152
43.

Protein disulfide isomerase blocks CEBPA translation and is up-regulated during the unfolded protein response in AML.

Haefliger S, Klebig C, Schaubitzer K, Schardt J, Timchenko N, Mueller BU, Pabst T.

Blood. 2011 Jun 2;117(22):5931-40. doi: 10.1182/blood-2010-08-304485. Epub 2011 Apr 6.

44.

Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.

Fos J, Pabst T, Petkovic V, Ratschiller D, Mueller BU.

Blood. 2011 May 5;117(18):4881-4. doi: 10.1182/blood-2010-11-320747. Epub 2011 Mar 9.

45.

Red cell exchange does not appear to increase the rate of allo- and auto-immunization in chronically transfused children with sickle cell disease.

Venkateswaran L, Teruya J, Bustillos C, Mahoney D Jr, Mueller BU.

Pediatr Blood Cancer. 2011 Aug;57(2):294-6. doi: 10.1002/pbc.22985. Epub 2011 Feb 4.

PMID:
21298771
46.

Activation of the unfolded protein response in human acute myeloid leukemia.

Schardt JA, Mueller BU, Pabst T.

Methods Enzymol. 2011;489:227-43. doi: 10.1016/B978-0-12-385116-1.00013-3.

PMID:
21266233
47.

Hydroxyurea for children with sickle cell disease: are we starting too late?

Mueller BU.

Pediatr Blood Cancer. 2011 Jan;56(1):3-4. doi: 10.1002/pbc.22858. Review. No abstract available.

PMID:
21058289
48.

The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML.

Eyholzer M, Schmid S, Wilkens L, Mueller BU, Pabst T.

Br J Cancer. 2010 Jul 13;103(2):275-84. doi: 10.1038/sj.bjc.6605751.

49.

Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia.

Wang ZJ, Fischer R, Chu Z, Mahoney DH Jr, Mueller BU, Muthupillai R, James EB, Krishnamurthy R, Chung T, Padua E, Vichinsky E, Harmatz P.

Magn Reson Imaging. 2010 Apr;28(3):363-71. doi: 10.1016/j.mri.2009.12.001. Epub 2010 Jan 12.

50.

Respiratory symptoms and acute painful episodes in sickle cell disease.

Jacob E, Sockrider MM, Dinu M, Acosta M, Mueller BU.

J Pediatr Oncol Nurs. 2010 Jan-Feb;27(1):33-9. doi: 10.1177/1043454209344578.

PMID:
20038672

Supplemental Content

Loading ...
Support Center